Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cabazitaxel Clear all
Completed Phase 3 Interventional Results available

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT01308580
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel (XRP6258), Prednisone (or Prednisolone)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
21
States / cities
Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 24, 2026, 5:17 PM EDT
Active, not recruiting Phase 2 Interventional

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

NCT04592237
View directory record Official record
Conditions
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
Cabazitaxel, Carboplatin, Cetrelimab, Niraparib
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 24, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer

NCT01500720
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Cabazitaxel, Topotecan
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Muscle Shoals, Alabama • Omaha, Nebraska • Lebanon, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Sep 24, 2026, 5:17 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

NCT01001221
View directory record Official record
Conditions
Neoplasms, Malignant
Interventions
cabazitaxel, gemcitabine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Detroit, Michigan • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Sep 24, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

NCT01308567
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel (XRP6258), Docetaxel (XRP6976), Prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
32
States / cities
Muscle Shoals, Alabama • Anaheim, California • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 24, 2026, 5:17 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 24, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

NCT04495179
View directory record Official record
Conditions
Progressive Metastatic Castrate-Resistant Prostate Cancer
Interventions
AZD4635, Durvalumab, Cabazitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Sacramento, California • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 24, 2026, 5:17 PM EDT
Recruiting Phase 1 Interventional

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

NCT05818683
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
Interventions
Pasritamig, Cetrelimab, Cabazitaxel, Docetaxel, Apalutamide, Enzalutamide, Darolutamide, Abiraterone acetate plus prednisone (AAP), Lutetium Lu-177 vipivotide tetraxetan, JNJ-101556143
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Sarasota, Florida • Grand Rapids, Michigan • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 5:17 PM EDT
Completed No phase listed Observational

Multi-academic Center Study of Xofigo Patients

NCT03419442
View directory record Official record
Conditions
Prostate Cancer, Castration Resistant
Interventions
Xofigo, Taxotere, Jevtana
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 24, 2026, 5:17 PM EDT
Recruiting Phase 2 Interventional

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

NCT06738303
View directory record Official record
Conditions
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Cabazitaxel and carboplatin, Lu-PSMA-617
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 24, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

NCT03934840
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Chicago, Illinois • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 24, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

Cabazitaxel - PF Induction Chemotherapy

NCT01379339
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Cabazitaxel 10mg/m2, Cabazitaxel 12.5mg/m2, Cabazitaxel 15mg/m2, Cabazitaxel 17.5mg/m2, Cabazitaxel 20mg/m2
Drug
Lead sponsor
Krzysztof Misiukiewicz
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Sep 24, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

NCT01513733
View directory record Official record
Conditions
Prostate Cancer
Interventions
tasquinimod, tasquinimod 0.25 mg; 0.5 mg, tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
Drug
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years to 79 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Sep 24, 2026, 5:17 PM EDT
Terminated Phase 2 Interventional Results available

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT02844582
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Stage IV Prostate Adenocarcinoma
Interventions
Cabazitaxel, Prednisone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 24, 2026, 5:17 PM EDT
Recruiting Phase 3 Interventional

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

NCT07213674
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
45
States / cities
Goodyear, Arizona • Tucson, Arizona • Duarte, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 24, 2026, 5:17 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
42
States / cities
Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 24, 2026, 5:17 PM EDT
Recruiting Phase 2 Interventional

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

NCT06632977
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging, Computed Tomography, Bone scan, FDG-Positron Emission Tomography, PSMA PET Scan, Biospecimen Collection, Carboplatin, Cabazitaxel, Abiraterone Acetate, Enzalutamide, Lutetium Lu 177 Vipivotide Tetraxetan
Other · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
108
States / cities
Birmingham, Alabama • Tucson, Arizona • Chico, California + 91 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 24, 2026, 5:17 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

NCT02202772
View directory record Official record
Conditions
Urothelial Carcinoma of the Urinary Bladder
Interventions
Cabazitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
Guarionex J. Decastro
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 24, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

NCT02985957
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nivolumab, Ipilimumab, Cabazitaxel, Prednisone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
15
States / cities
Tucson, Arizona • Marietta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 24, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

NCT01438307
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC, Metastatic NSCLC
Interventions
Cabazitaxel-XRP6258 (3-week cycle), Cabazitaxel-XRP6258 (5-week cycle)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Birmingham, Alabama • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Sep 24, 2026, 5:17 PM EDT
Terminated Phase 1 Interventional

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

NCT03043989
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Cabazitaxel, Clarithromycin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 24, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

NCT01140607
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
Cabazitaxel (XRP6258)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
La Jolla, California • Loma Linda, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2015 · Synced Sep 24, 2026, 5:17 PM EDT
Terminated Phase 2 Interventional Results available

Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer

NCT01845792
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel with Abiraterone Acetate, Cabazitaxel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 95 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 24, 2026, 5:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

NCT01751308
View directory record Official record
Conditions
Malignant Solid Tumor - Malignant Nervous System Neoplasm
Interventions
Cabazitaxel (XRP6258)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 18 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Sep 24, 2026, 5:17 PM EDT